Sera Prognostics
Sera Prognostics: Enhancing pregnancy care through precision biomarker-based tests.
Founded
2008Sera Prognostics: Enhancing pregnancy care through precision biomarker-based tests.
Founded with a mission to improve the lives of women and babies, Sera Prognostics is a proteomic and bioinformatics company specializing in precision biomarker-based tests for pregnancy care. The company's core vision is to provide pivotal information early in pregnancy to physicians, enabling them to enhance care and outcomes for pregnant women and their newborns. Sera Prognostics offers diagnostic tests that predict the risk of spontaneous premature birth and other pregnancy complications, focusing on high-value women's health diagnostics.
Sera Prognostics has attracted notable investors and affiliations, contributing to its growing impact in the healthcare sector. The company has achieved significant milestones, including the development and commercialization of its PreTRM® test, which assesses the risk of preterm birth. By delivering critical insights to healthcare providers, Sera Prognostics aims to improve both clinical outcomes and health economics, positioning itself as a leader in the field of pregnancy diagnostics.
Companies similar to Sera Prognostics include Carmenta Bioscience, Proteogenix, Chosen Diagnostics and Predictive Health Diagnostics Company.
Sera Prognostics was founded in 2008.
Sera Prognostics' headquarters is located in Salt Lake City, UT, US.
Sera Prognostics' most recent funding round was for $100M (USD) in April 2021.
As of Apr 28, 2021, Sera Prognostics has disclosed funding of $245.6M (USD). Undisclosed round amounts are excluded.
Sera Prognostics has 113 employees as of Feb 6, 2024.
Predictive Health Diagnostics Company
